Syndax Pharmaceuticals Inc (SNDX)
R&D to Revenue
93.47%
Quarterly · Period ending:
SNDX R&D to Revenue
Latest reported93.47%period ending
Latest reported93.47%period ending
SNDX Quarterly R&D/Revenue (0.00% → 93.47%)
Latest values, visible window
High-resolution chart · PNG
SNDX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 93.4715% | |
| 90.7206% | |
| 114.8362% | |
| 122.6919% | |
| 163.9365% | |
| 307.5342% | |
| 853.2422% | |
| 567.768% | |
| 1,390.1429% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 18.8819% | |
| 206.9172% | |
| 4,451.4512% | |
| 5,770.4485% | |
| 4,084.7368% | |
| 3,801.5831% | |
| 2,887.3351% | |
| 2,522.9551% | |
| 2,500.5263% | |
| 2,618.2058% | |
| 3,242.7441% | |
| 2,975.9894% | |
| 4,163.4211% | |
| 3,718.9974% | |
| 3,918.4697% | |
| 4,047.2296% | |
| 1,391.3663% | |
| 3,996.0656% | |
| 3,233.4426% | |
| 3,131.8033% | |
| 2,778.3607% | |
| 4,024.2623% | |
| 2,010.1639% | |
| 1,569.1803% | |
| 848.1967% | |
| 973.1148% | |
| 13,358.8235% | |
| 0% | |
| 0% | |
| 142.4167% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |